Piper Sandler Sees Path to Growth for Bristol-Myers Squibb Company (BMY) After Eliquis Patent Expiry

Core Viewpoint - Bristol-Myers Squibb Company (NYSE:BMY) is considered a safe stock for starter portfolios, with analysts highlighting its potential for recovery in top-line growth despite the upcoming loss of exclusivity for Eliquis in 2028 [1] Group 1: Analyst Ratings and Price Targets - Piper Sandler raised its price target for Bristol-Myers Squibb to $75 from $66 while maintaining an Overweight rating, indicating confidence in the company's future performance [1] - RBC Capital initiated coverage with a Sector Perform rating and set a price target of $60, noting that Bristol-Myers has the most extensive Phase 3 pipeline among large-cap pharmaceutical companies [3] Group 2: Growth Avenues - The company has two main avenues for regaining top-line growth: the efficacy of milvexian in the LIBREXIA AF study for atrial fibrillation and advancements in its pipeline, including label upgrades for Cobenfy, admilparant, CELMoD treatments like iberdomide and mezigdomide, and ryz101 [2] Group 3: Company Overview - Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing, and delivering medicines for serious diseases, including cancer, blood disorders, immune conditions, cardiovascular disease, and neurological disorders [4]